bioMérieux S.A. (BMXXY)
OTCMKTS
· Delayed Price · Currency is USD
12.95
0.00 (0.00%)
At close: May 9, 2025
bioMérieux Revenue
In the year 2024, bioMérieux had annual revenue of 3.98B EUR with 8.31% growth. bioMérieux had revenue of 2.08B in the half year ending December 31, 2024, with 7.61% growth.
Revenue
3.98B EUR
Revenue Growth
+8.31%
P/S Ratio
3.85
Revenue / Employee
269.75K EUR
Employees
14,754
Market Cap
15.88B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.98B | 305.20M | 8.31% |
Dec 31, 2023 | 3.67B | 85.60M | 2.39% |
Dec 31, 2022 | 3.59B | 212.90M | 6.31% |
Dec 31, 2021 | 3.38B | 258.00M | 8.27% |
Dec 31, 2020 | 3.12B | 443.40M | 16.58% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
American Oncology Network | 1.76B |